Not available
Quote | Coherus BioSciences Inc. (NASDAQ:CHRS)
Last: | $2.39 |
---|---|
Change Percent: | 0.0% |
Open: | $2.42 |
Close: | $2.39 |
High: | $2.51 |
Low: | $2.36 |
Volume: | 2,098,664 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
News | Coherus BioSciences Inc. (NASDAQ:CHRS)
2024-03-20 20:14:44 ET Summary CHRS has sold Cimerli, a Lucentis biosimilar, to SDZNY. CHRS anti-IL-27 antibody, casdozokitug, shows promising results as part of a triple therapy in hepatocellular carcinoma, with an overall response rate of 38%. Numbers on market share point t...
2024-03-14 18:28:43 ET The final set of results for Coherus Biosciences ' (NASDAQ: CHRS) 2023 was released after market hours on Wednesday, and investors reacted with displeasure the following day. They traded the stock down by more than 6% Thursday, a much steeper fall than the 0.6...
Message Board Posts | Coherus BioSciences Inc. (NASDAQ:CHRS)
Subject | By | Source | When |
---|---|---|---|
MomentumIts gaining last up | DewDiligence | investorshub | 05/09/2023 8:42:13 PM |
$CHRS good read | DewDiligence | investorshub | 05/08/2023 4:47:45 PM |
short data if anyone is interested | dinogreeves | investorshub | 05/08/2023 11:07:14 AM |
should we be shorting? | DewDiligence | investorshub | 05/08/2023 6:16:37 AM |
$CHRS must see | dinogreeves | investorshub | 05/08/2023 5:57:13 AM |
News, Short Squeeze, Breakout and More Instantly...
Coherus BioSciences Inc. Company Name:
CHRS Stock Symbol:
NASDAQ Market:
Coherus BioSciences Inc. Website:
2024-03-14 18:28:43 ET The final set of results for Coherus Biosciences ' (NASDAQ: CHRS) 2023 was released after market hours on Wednesday, and investors reacted with displeasure the following day. They traded the stock down by more than 6% Thursday, a much steeper fall than the 0.6...
– Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 – – UDENYCA® net sales of $36.2 million in the fou...
– Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 – – UDENYCA ® net sales of $36.2 million in the fourth quarter and $127.1 million in FY 2023 – – CIMERLI ® net sales of $52.4 milli...